Parkinson Clinical Trials
Here are the 6 most popular medical studies for parkinson
Norepinephrine Precursor
Droxidopa for Freezing of Gait
Since droxidopa has been approved in Japan for treating freezing of gait in Parkinson's disease patients, this is to confirm and further investigate the safety and efficacy using a similar dose. The possible beneficial effects on cognition in mildly cognitively impaired Parkinson's disease patients will also be tested, since this problem in Parkinson's disease may be associated with decreased brain synthesis of norepinephrine (a neurotransmitter associated with multiple brain functions). During this 11 week study, droxidopa will be slowly titrated up to 600 mg daily. Walking and freezing of gait will be evaluated and rated. Cognitive functions will be evaluated by a computer-based program.
Behavioural Intervention
CranioSacral Therapy for Parkinson's Disease
This trial is studying the effect of CranioSacral Integrative therapy on Parkinson's Diseased Patients. This therapy is given biweekly for 3 months, and the investigators expect to see a positive change in the symptoms of the patients.
Popular filter options for parkinson trials
Parkinson's Disease Clinical Trials
View 96 Parkinson's Disease medical studies.
Vitamin Supplementation
PD vitamin supplementation +2 More for Parkinson's Disease
This experiment seeks to determine whether individuals with PD will benefit from vitamin B6 (pyridoxine hydrochloride), B12 (cyanocobalamin), and Folic Acid supplementation, whether they will benefit from a 6-week circuit training program, or whether they will benefit from a combination of the two interventions. The outcome variables will include: plasma homocysteine, GSH:GSSG ratio, cognitive function, balance, strength, functional activities, kinematic gait analysis, and a quality of life questionnaire.
Nicotinic Acetylcholine Receptor Agonist
Nicotine patch +1 More for Parkinson's Disease
The specific aims of this study are to examine whether treatment with transdermal nicotine improves computer-based laboratory and clinical measures of impulsive and compulsive behaviors in Parkinson's Disease subjects who have recently experienced an impulse control disorder.
Monoamine Oxidase Inhibitor
Rasagiline for Parkinson's Disease
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
Behavioral Intervention
Cognitive Behavioral Therapy for Parkinson's Disease
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Radiation Therapy
Far Infrared Radiation for Parkinson's Disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Radioactive Drug
[123I]β-CIT for Parkinson's Disease
This trial is testing a new strategy to identify people at risk for Parkinson's disease before they show any symptoms. The strategy involves combining two biomarkers of parkinsonism, olfaction and brain imaging, with a radioactively labeled drug. First-degree relatives of PD patients will be recruited to participate in this study.
PD Clinical Trials
View 96 PD medical studies.
Vitamin Supplementation
PD vitamin supplementation +2 More for Parkinson's Disease
This experiment seeks to determine whether individuals with PD will benefit from vitamin B6 (pyridoxine hydrochloride), B12 (cyanocobalamin), and Folic Acid supplementation, whether they will benefit from a 6-week circuit training program, or whether they will benefit from a combination of the two interventions. The outcome variables will include: plasma homocysteine, GSH:GSSG ratio, cognitive function, balance, strength, functional activities, kinematic gait analysis, and a quality of life questionnaire.
Nicotinic Acetylcholine Receptor Agonist
Nicotine patch +1 More for Parkinson's Disease
The specific aims of this study are to examine whether treatment with transdermal nicotine improves computer-based laboratory and clinical measures of impulsive and compulsive behaviors in Parkinson's Disease subjects who have recently experienced an impulse control disorder.
Monoamine Oxidase Inhibitor
Rasagiline for Parkinson's Disease
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
Behavioral Intervention
Cognitive Behavioral Therapy for Parkinson's Disease
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Radiation Therapy
Far Infrared Radiation for Parkinson's Disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Radioactive Drug
[123I]β-CIT for Parkinson's Disease
This trial is testing a new strategy to identify people at risk for Parkinson's disease before they show any symptoms. The strategy involves combining two biomarkers of parkinsonism, olfaction and brain imaging, with a radioactively labeled drug. First-degree relatives of PD patients will be recruited to participate in this study.
Parkinson Clinical Trials With No Placebo
View 96 parkinson medical studies that do not have a placebo group.
Vitamin Supplementation
PD vitamin supplementation +2 More for Parkinson's Disease
This experiment seeks to determine whether individuals with PD will benefit from vitamin B6 (pyridoxine hydrochloride), B12 (cyanocobalamin), and Folic Acid supplementation, whether they will benefit from a 6-week circuit training program, or whether they will benefit from a combination of the two interventions. The outcome variables will include: plasma homocysteine, GSH:GSSG ratio, cognitive function, balance, strength, functional activities, kinematic gait analysis, and a quality of life questionnaire.
Behavioral Intervention
Cognitive Behavioral Therapy for Parkinson's Disease
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Radiation Therapy
Far Infrared Radiation for Parkinson's Disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Radioactive Drug
[123I]β-CIT for Parkinson's Disease
This trial is testing a new strategy to identify people at risk for Parkinson's disease before they show any symptoms. The strategy involves combining two biomarkers of parkinsonism, olfaction and brain imaging, with a radioactively labeled drug. First-degree relatives of PD patients will be recruited to participate in this study.
Monoamine Oxidase Inhibitor
Selegiline +1 More for Erectile Dysfunction
The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together. Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are not receiving complete benefit from carbidopa/levodopa. Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic hyperplasia (BPH).
View More Parkinson Trials
See another 75 medical studies focused on parkinson.
Frequently Asked Questions
Introduction to parkinson
What are the top hospitals conducting parkinson research?
While clinical trials for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) may still be in their early stages, several top hospitals are leading the way in advancing our understanding and treatment of this complex condition. In Toronto, the Toronto Western Hospital is currently conducting six active Parkinson's trials, showcasing its commitment to finding innovative solutions for patients. Moving south to Chicago, Rush University Medical Center has five ongoing trials focused solely on Parkinson's disease. This renowned institution is at the forefront of research and has made significant strides in improving the lives of those affected by this neurodegenerative disorder.
On the West Coast, Stanford University also prioritizes Parkinson's research with four active clinical trials. The expertise and dedication of its medical professionals contribute to groundbreaking advancements that offer hope to individuals living with Parkinson's. Meanwhile, even away from major cities like Chicago or Toronto, specialized centers like the Parkinson's Disease and Movement Disorders Center of Boca Raton are making a difference too. They're actively involved in three ongoing clinical trials dedicated exclusively to exploring new treatments for patients.
Lastly, Northwestern University in Chicago deserves recognition for its contributions as well; it is currently running three active clinical studies focused on treating and managing symptoms associated with Parkinson’s disease while earnestly working towards breakthroughs that could revolutionize how we approach this neurological condition.
These hospitals are not only providing cutting-edge care but also offering opportunities for patients to participate in ground-breaking research studies that have enormous potential implications worldwide- an exciting prospect considering there remain no previously concluded records available within these institutions specifically targeting parkinsonism thus far! Such initiatives pave way forward creating brighter outlooks against Parkinons' fight
Which are the best cities for parkinson clinical trials?
When it comes to clinical trials for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease), several cities are at the forefront of research and advancement. New york, New York leads the pack with 19 active trials exploring treatments such as BIIB122, ExAblate Pallidotomy, and LY3884961. Philadelphia, Pennsylvania closely follows with 17 ongoing studies focused on ABBV-951, Investigational Treatment 1, and RO7486967 Arm. Additionally, Chicago in Illinois is conducting 14 active trials investigating ABBV-951, BIIB122, and Tavapadon. Lastly Los Angeles in California and Tampa in Florida both have 13 active trials each studying various potential breakthroughs like Movement task and IkT-148009 respectively. These cities offer individuals with Parkinson's disease access to cutting-edge clinical trials that may lead to new treatment options and improved quality of life.
Which are the top treatments for parkinson being explored in clinical trials?
Clinical trials are at the forefront of [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research, with several promising treatments currently being explored. One standout option is gene therapy, which aims to correct genetic abnormalities associated with the condition. Another avenue under investigation is deep brain stimulation (DBS), where electrodes are implanted in specific regions of the brain to alleviate symptoms. Additionally, researchers are looking into novel medications that target specific pathways involved in Parkinson's progression, providing hope for improved treatment options in the future.
What are the most recent clinical trials for parkinson?
Exciting advancements in [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research are underway through recent clinical trials. One promising trial is evaluating the effectiveness of Waitlist Couple Pairs Parkinson's Group, a Phase 2 study that aims to improve outcomes for patients with Parkinson's. Another Phase 2 trial focuses on IkT-148009 and its potential benefits in managing the symptoms of this neurodegenerative disorder. In addition, Terazosin therapy is being investigated in a Phase 2 trial to assess its efficacy as a treatment option. These studies offer hope for improved quality of life and better management strategies for individuals living with Parkinson's disease.
What parkinson clinical trials were recently completed?
Several recent clinical trials have made significant advancements in the field of [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research. Notably, a trial sponsored by AbbVie completed in September 2021 focused on evaluating the efficacy of ABBV-951, a potential treatment option for this neurodegenerative disorder. Additionally, Biogen concluded their study on BIIB054, another promising therapy for Parkinson's disease, in June 2021. These important milestones highlight the ongoing efforts to discover innovative treatments that could potentially improve the lives of individuals living with Parkinson's disease.